Royalty Pharma (RPRX) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook ...

Patient Capital Management, a value investing firm, released its “Patient Capital Opportunity Equity Strategy” first quarter ...

BofA raised the firm’s price target on Royalty Pharma (RPRX) to $42 from $41 and keeps a Buy rating on the shares. The firm, in its preview of ...

Royalty Pharma announces $0.22 dividend per share for Q2 2025, payable on June 10 to shareholders of record by May 16. Royalty Pharma plc has announced that its board of directors has approved a ...

Investing.com -- Moody’s Ratings has uplifted the rating of Royalty Pharma plc’s senior unsecured notes from Baa3 to Baa2. The outlook for the company has also been revised, shifting from positive to ...

NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2025 of $0.22 per Class A ...

Shares of Royalty Pharma plc (NASDAQ:RPRX – Get Free Report) have been given a consensus recommendation of “Buy” by the five ratings firms that are covering the company, MarketBeat.com reports.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In its first-quarter 2025 investor letter, Patient Capital Opportunity Equity Strategy highlighted stocks such as Royalty Pharma plc (NASDAQ:RPRX). Royalty Pharma plc (NASDAQ:RPRX) is a buyer of ...

NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2025 of $0.22 per Class A ...